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Received February 21, 2016; accepted July 18, 2016AbstractImmune checkpoint inhibition with blocking antibodies that target cytotoxic T-lymphocyte antigen-4 (CTLA-4) and the programmed cell
death protein 1 (PD-1) pathway [PD-1/programmed death-ligand 1 (PD-L1)] have demonstrated promise in a variety of malignancies. While
ipilimumab has been approved as a CTLA-4 blocking antibody by the US Food and Drug Administration for the treatment of advanced
melanoma, it is still not approved for lung cancer treatment. In contrast, nivolumab and pembrolizumab, both PD-1 blocking antibodies, have
been approved for second-line treatment of nonsmall cell lung cancer in 2015 because of their high potency and long-lasting effects in some
patient subgroups. Other PD-1 and PD-L1 monoclonal antibodies are also in active development phase. Treatment with such immune checkpoint
inhibitors is associated with a unique pattern of immune-related adverse events or side effects. Combination approaches involving CTLA-4 and
PD-1/PD-L1 blockade or checkpoint inhibitors with chemotherapy or radiotherapy are being investigated to determine whether they may
enhance the efficacy of treatment. Despite many challenges ahead, immunotherapy with checkpoint inhibitors has already become a new and
important treatment modality for lung cancer in the last decade following the discovery of targeted therapy.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Lung cancer is the leading cause of cancer-related deaths in
Taiwan and other developed countries in the world. The 5-year
survival rate was only 15.9%, with a median survival of 13.2
months, in Taiwan between 2002 and 2008.1
There are two arms of the immune system, the innate and
the adaptive, which protect the body from foreign agents. The
innate immune system includes physical epithelial barriers,
phagocytes, natural killer cells, and circulating complement
proteins. The innate immune system is the first line of defenseConflicts of interest: The author declares that he has no conflicts of interest
related to the subject matter or materials discussed in this article.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).against pathogens. In contrast, the adaptive arm of the immune
system is dormant until it is primed by the presence of a
pathogen that has evaded or overwhelmed the innate immu-
nity. Components of the adaptive immune system include both
B cells and T cells. Naïve B cells are activated to produce
antigen-recognizing antibodies when they are presented with
antigens from a pathogen. When foreign antigens are pre-
sented to naïve T cells, they mature into one of two types of
effector T cells: CD4þ helper T cells that facilitate antibody
production, and CD8þ cytotoxic T cells that directly kill cells
recognized as foreign (such as viral infected cells or tumor
cells); this process is called cell-mediated immunity. The
adaptive immune response is initiated when tumor cell anti-
gens released by innate immunity are taken up by dendritic
cells. These dendritic cells then migrate to the draining lymph
nodes, where they present these tumor antigens to T cells,
causing them to mature into cytotoxic T cells to destroy tumor
cells (Fig. 1).sevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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recognizing, controlling, and eradicating cancer, cancer in-
duces immunosuppression through several mechanisms that
may suppress effective antitumor immunity, including but not
limited to: (1) secretion of immunosuppressive cytokines; (2)
loss of major histocompatibility complex antigen expression;
(3) and programmed cell death protein 1/programmed cell
death protein 1 ligand (PD-1/PD-L1) interaction of tumor cells
with immune cells.2e6 In the past, immunotherapy has had
minimal success in lung cancer treatment, which was attrib-
uted in part to the belief that lung cancer is non-
immunogenic.7e11 Most patients present with advanced
disease and are immunosuppressed, as documented by
decreased lymphocyte counts and cytotoxic function seen in
this patient population.8,11e13 Regulatory T-cells (CD4þ Treg)
are a subpopulation of lymphocytes that play an important role
in suppressing tumor immune surveillance, and have been
found to have higher levels in peripheral blood and tumor
microenvironment of lung cancer patients compared with
other T-cell subpopulations.14 CD4þ Treg suppress cytotoxic
T-cell functions that are responsible for killing tumor cells. We
previously also showed that double signal stimulation is
needed for these immunosuppressed lymphocytes to recover
their cytotoxic function against tumor cells.9,15e18
It was recently found that cancer cells can prevent them-
selves from immune surveillance and killing through adaptive
immune resistance, causing the disabling of tumor-specific T
cells (Fig. 2).19,20 Many types of cancers have been found to
express PD-L1 on their tumor cell surfaces, which is a known
ligand of the PD-1 receptor on T cells. This pathway of
interaction between PD-1 and PD-L1 causes T-cellFig. 1. T-cell activation phase and the cytotoxic T-lymphocyte antigen-4 (CTLA-4)
context of a major histocompatibility complex (MHC) molecule in addition to the c
with CD28 on a T cell. Soon after activation, CTLA-4 is translocated to the pl
immunologic homeostasis.downregulation and functional inhibition.5,6 There are two
immune checkpoint inhibitory pathways that involve signaling
through CTLA-4 or PD-1 with their ligands (Figs. 1 and 2).
Antibody therapies against these negative immunologic regu-
lators have demonstrated significant success in lung cancer
treatment in recent years. This review focuses on antibodies
that block the CTLA-4 and PD-1/PD-L1 pathways. We discuss
the preclinical rationale and clinical experience with these
antibodies in nonsmall cell lung cancer (NSCLC) treatment.
2. Cytotoxic T-lymphocyte antigen-4 pathway
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is a receptor
that is expressed on the T-cell surface during the T-cell acti-
vation phase. Activation of the T-cell requires both antigen
presentation in the context of a major histocompatibility
complex molecule and a costimulatory signal stimulation by
B7 from an antigen-presenting cell to interact with CD28 on
the T-cell. Early after T-cell activation, CTLA-4 is trans-
located to the plasma membrane of the T-cell. CTLA-4 binds
members of the B7 family with a much higher affinity than
CD28, where it downregulates the function of activated T-cells
(Fig. 1). CTLA-4 downregulates activated T-cell function not
only through preventing costimulation by outcompeting CD28
for its ligand, B7, but also by inducing T-cell cycle arrest.21e24
Through these mechanisms, CTLA-4 has an essential role in
maintaining normal immunologic homeostasis, as evidenced
by the fact that mice deficient in CTLA-4 died from fatal
lymphoproliferative disease.25
CTLA-4 also regulates tumor immunity via Treg that ex-
presses high levels of surface CTLA-4. CTLA-4-expressingimmunologic checkpoint. T-cell activation requires antigen presentation in the
ostimulatory signal stimulation when B7 on an antigen-presenting cell interacts
asma membrane where it downregulates the function of T cells to maintain
Fig. 2. T-cell effector phase and the programmed cell death protein 1 (PD-1) immunologic checkpoint. PD-1 is expressed on activated T cells. Interactions between
PD-1 and its ligands, programmed death-ligand (PD-L)1 and PD-L2, are complex and occur at many steps of an immune response. An interaction soon after
activation in the lymph node where PD-L1 or PD-L2 on an antigen-presenting cell negatively regulates T-cell activity through PD-1 and through an interaction
between B7 and PD-L1. The PD-1 pathway is important in the tumor microenvironment, where PD-L1 expressed by tumors interacts with PD-1 on T cells to
suppress T-cell effector function.
9Y.-M. Chen / Journal of the Chinese Medical Association 80 (2017) 7e14Tregs may facilitate nonresponsiveness of the immune system
to tumor antigens.26 Tregs have been shown to be present in
tumors and coexist with primed effector T cells. Thus,
blocking Treg function through anti-CTLA-4 antibodies may
have the potential to remove Treg suppression and enhance
antitumor immunity.
Based on preclinical studies that demonstrated antibody
blockades of CTLA-4 could result in antitumor immunity,27,28
two antibodies targeting CTLA-4, ipilimumab (Bristol-Myers
Squibb, Princeton, NJ, USA) and tremelimumab (MedI-
mmune/AstraZeneca, Wilmington, DE, USA) entered clinical
development. Early reports on both agents showed durable
clinical responses in some patients, particularly melanoma
patients.29e31 Ipilimumab is a fully human anti-CTLA-4
monoclonal antibody that is now approved for the treatment
of melanoma.32
The rationale for the combined use of anti-CTLA-4 anti-
body with chemotherapy is based on the assumption that
tumor-specific antigens will be released during chemotherapy-
induced tumor necrosis and that will augment tumor-specific
immune reactions. Ipilimumab plus chemotherapy showed
promising results in a phase II CA184-041 study that ran-
domized previously untreated advanced NSCLC patients to
receive paclitaxel plus carboplatin, alone or in association with
concurrent ipilimumab (10 mg/kg from Cycle 1 to Cycle 4) or
with phased ipilimumab (10 mg/kg from Cycle 3 to Cycle
6).33 There were 204 patients included in this study. Response
was assessed by using immune-related response criteria and
modified World Health Organization criteria.34,35 This study
met its primary end point of improved immune-relatedprogression-free survival (PFS) for phased ipilimumab versus
the control [hazard ratio (HR)¼ 0.72, p¼ 0.05], but not for
concurrent ipilimumab (HR¼ 0.81, p¼ 0.13). For the phased
arm, concurrent arm, and control arm, the median immune-
related PFSs were 5.7 months, 5.5 months, and 4.6 months,
respectively; median PFSs of 5.1 months, 4.1 months, and 4.2
months, respectively; immune-related best overall response
rates of 32%, 21%, and 18%, respectively; and best overall
response rates of 32%, 21%, and 14%, respectively.
A phase III study of paclitaxel/carboplatin with or without
ipilimumab in treatment-naive squamous NSCLC is ongoing.
Another CTLA-4-blocking antibody, tremelimumab (CP-
675,206) is a fully human immunoglobulin G (IgG)-2 mono-
clonal antibody. Tremelimumab has induced durable tumor
responses in patients with melanoma in a phase I/II clinical
trial.36 However, a phase III trial was discontinued after review
of interim data showed that the trial would not demonstrate
superiority to conventional standard chemotherapy.37 Trem-
elimumab has shown promising responses in patients with
malignant mesothelioma.38
3. PD-1/PD-L1 pathway
Successful treatment targeting CTLA-4 has created enthu-
siasm for approaches targeting other immunologic check-
points. Among them, the PD-1/PD-L1 axis has been most
actively studied (Figure 2). PD-1 is a negative regulator of T-
cell activity that limits the activity of T cells, especially in the
effector phase, when it interacts with its two ligands PD-L1
and PD-L2.5,39,40 When engaged by the ligand, PD-1
10 Y.-M. Chen / Journal of the Chinese Medical Association 80 (2017) 7e14inhibits kinase signaling pathways that normally lead to T-cell
activation.5 Mice that are deficient in PD-1 have a different
and distinct autoimmune phenotype from mice deficient in
CTLA-4.41,42 PD-1 is expressed on many types of lympho-
cytes, including B cells and natural killer cells.40,43
There are several antibodies that disrupt the PD-1 axis that
have entered clinical development; two of them (nivolumab,
Bristol-Myers Squibb, New York, NY, USA; pembrolizumab,
Merck, Whitehouse Station, NJ, USA) have Food and Drug
Administration (FDA) approval for second-line treatment of
NSCLC (Table 1). These antibodies can be classified into two
main categories: those that target PD-1 and those that target
PD-L1.3.1. NivolumabNivolumab (ONO-4538, BMS-936558) is a human IgG4
monoclonal antibody that targets the PD-1 receptor.44e47 A
report of the long-term follow-up of 129 patients with heavily
pretreated NSCLC who entered a phase I dose-escalation
cohort expansion trial of nivolumab 1 mg/kg, 3 mg/kg, or
10 mg/kg intravenously (IV) once every 2 weeks revealed that
1-, 2-, and 3-year overall survival (OS) rates were 42%, 24%,
and 18%, respectively, across doses, and were 56%, 42%, and
27%, respectively, at the 3 mg/kg dose (n¼ 37) chosen for
further clinical development.45 Response rates were similar in
squamous (16.7%) and nonsquamous (17.6%) NSCLC. A
phase II trial of squamous type NSCLC was performed in
France, Germany, Italy, and the USA. Patients with squamous
NSCLC who had received two or more previous treatments
received IV nivolumab (3 mg/kg) every 2 weeks until pro-
gression or unacceptable toxic effects. Between 2012 and
2013, 117 patients were enrolled.44 Seventeen (14.5%) of 117
patients had an objective response. The response rate was 14%
in patients with tumor PD-L1 expression< 5% and 24% in
those with expression 5%. A phase III trial was done on 272
squamous NSCLC patients who had disease progression dur-
ing or after first line chemotherapy (CheckMate 017).46 Pa-
tients were randomized to receive nivolumab 3 mg/kg every 2
weeks, or docetaxel 75 mg/m2 every 3 weeks. The median OS
was 9.2 months with nivolumab versus. 6.0 months with
docetaxel (HR¼ 0.59, p< 0.001). One-year survival rate was
42% with nivolumab versus 24% with docetaxel. The responseTable 1
Immune checkpoint inhibitors in development for nonsmall cell lung cancer.
Inhibitor Target Monoclonal antibo
Nivolumab (ONO-4538, BMS-936558) PD-1 Fully human IgG4
Pembrolizumab (MK-3475) PD-1 Humanized IgG4
Atezolizumab (MPDL3280A) PD-L1 Human IgG1
Durvalumab (MEDI-4736) PD-L1 Fully human IgG1
Avelumab (MSB0010718C) PD-L1 Fully human IgG1
Ipilimumab CTLA-4 Fully human IgG1
Tremelimumab (CP-675,206) CTLA-4 Fully human IgG2
CTLA-4¼ cytotoxic T-lymphocyte antigen-4; FDA¼ Food and Drug Administrati
L1¼ programmed cell death-ligand 1rate was 20% with nivolumab versus 9% with docetaxel
( p¼ 0.008). The median PFS was 3.5 months with nivolumab
versus 2.8 months with docetaxel (HR¼ 0.62, p< 0.001). The
expression of the PD-L1 was neither prognostic nor predictive
of treatment benefit. The US FDA granted approval to nivo-
lumab for the treatment of metastatic squamous NSCLC pa-
tients with progression on or after platinum-based
chemotherapy in 2015.
In CheckMate 057, patients with nonsquamous NSCLC
that had progressed during or after platinum-based chemo-
therapy were randomized to receive nivolumab or docetaxel.47
The median OS was 12.2 months among 292 patients in the
nivolumab arm and 9.4 months among 290 patients in the
docetaxel arm (HR¼ 0.73, p¼ 0.002). One-year survival rate
was 51% with nivolumab versus 39% with docetaxel. The
response rate was 19% with nivolumab versus 12% with
docetaxel ( p¼ 0.02). Based on these data, the FDA approved
nivolumab for the treatment of metastatic NSCLC patients
with progression on or after platinum-based chemotherapy
recently. This approval expands the indication for nivolumab
in NSCLC to include nonsquamous histologies.
A phase I study evaluating the efficacy and safety of
nivolumab monotherapy in patients with chemotherapy naïve
advanced NSCLC was reported recently.48 There were 52
advanced NSCLC patients who received nivolumab 3 mg/kg
IV every 2 weeks until disease progression or unacceptable
toxicity. Preliminary results showed that the response rate
(RR) was 21% (11/52). Objective RRs for subgroups were
23% (9/39) in nonsquamous and 15% (2/13) in squamous
NSCLC. Objective responses were 31% (8/26) in PD-L1
positive patients and 10% (2/21) in PD-L1 negative patients.
Nivolumab has been combined with platinum-based
chemotherapy or anti-CTLA4 immunotherapy as first-line
treatment for advanced NSCLC, or with epidermal growth
factor receptor (EGFR)-tyrosine kinase inhibitor targeted
therapy for EGFR-tyrosine kinase inhibitor acquired
resistance.49e51 The data are too premature to be discussed.3.2. PembrolizumabPembrolizumab (MK-3475, lambrolizumab, Keytruda,
Kenilworth, NJ, USA) is an IgG4-engineered humanized anti-
body that targets the PD-1 receptor. A recently published paperdy type Company Development phase
Ono Pharmaceutical/Bristol-Myers
Squibb
FDA-approved
Merck Sharp & Dohme FDA-approved
Genentech/Roche III
MedImmune/Astra-Zeneca III
Merck/Pfizer III
Bristol-Myers Squibb III
MedImmune/Pfizer III
on; IgG¼ immunoglobulin G; PD-1¼ programmed cell death protein 1; PD-
11Y.-M. Chen / Journal of the Chinese Medical Association 80 (2017) 7e14included 495 NSCLC patients who received pembrolizumab (at
a dose of either 2 mg/kg or 10 mg/kg every 3 weeks or 10 mg/
kg every 2 weeks) as part of the international phase 1
KEYNOTE-001 trial.52 Among all the NSCLC patients, the
objective RR was 19.4%, and the median duration of response
was 12.5 months. The median duration of OS was 12.0 months.
Among patients with a PD-L1 proportion score of at least 50%,
the RR was 45.2% in the validation group. Among all the
patients with a proportion score of at least 50%, median PFS
was 6.3 months. The US FDA granted accelerated approval to
pembrolizumab for metastatic NSCLC treatment in patients
whose tumors expressed PD-L1, as determined by an FDA-
approved test, with disease progression during or after
platinum-containing chemotherapy in 2015.53
The KEYNOTE-021 trial evaluated the safety, tolerability,
and clinical activity of pembrolizumab plus platinum-based
doublet chemotherapy for treatment-naïve patients with
advanced NSCLC.54 Patients were randomized 1:1 to pem-
brolizumab 2 or 10 mg/kg every 3 weeks plus carboplatin and
paclitaxel (Cohort A; any histology) or carboplatin plus
pemetrexed (Cohort C; nonsquamous without EGFR sensi-
tizing mutation nor anaplastic lymphoma kinase trans-
location). Patients received pembrolizumab plus
chemotherapy for four cycles followed by pembrolizumab
maintenance therapy in Cohort A and pembrolizumab plus
pemetrexed maintenance therapy in Cohort C. As of
December 2014, 44 patients were treated. Preliminary RR was
30% in Cohort A and 58% in Cohort C.
Since combined anti-PD-1 and anti-CTLA-4 treatment has
shown robust efficacy and manageable toxicity in patients with
melanoma, a phase 1 study evaluating pembrolizumab plus
ipilimumab was performed in NSCLC patients.55 Patients with
NSCLC that recurred after no more than two prior regimens
received pembrolizumab plus ipilimumab every 3 weeks for
four cycles followed by maintenance pembrolizumab therapy.
The preliminary data demonstrated an acceptable toxicity
profile and robust antitumor activity for pembrolizumab plus
ipilimumab in patients with recurrent NSCLC.
Regarding immunotherapy in NSCLC patients with brain
metastases, a preliminary report of phase II pembrolizumab on
patients with at least one brain metastasis that was previously
untreated or progressing after prior local therapy showed
promising results, with four of an initial nine patients who had
brain metastatic lesion showing partial response to the treat-
ment.56 The study is still ongoing.3.3. AtezolizumabAtezolizumab (MPDL3280A) is a humanized, engineered
monoclonal antibody of IgG1 against PD-L1. Preliminary re-
sults of two phase II trials in NSCLC were reported recently.
One of the studies (POPLAR, n¼ 287) was a randomized trial
with docetaxel as the control arm; the data showed that ate-
zolizumab significantly improved OS.57 In this study, previ-
ously treated NSCLC patients were randomized to receive
atezolizumab 1200 mg IV every 3 weeks or docetaxel 75 mg/
m2 IV every 3 weeks. PD-L1 expression was evaluated usingthe SP142 antibody assay. Patients were grouped as tumor cell
PD-L1 staining (TC) 0, 1, 2, or 3 and immune cell PD-L1
staining (IC) 0, 1, 2, or 3. Improved efficacy was found with
increasing PD-L1 expression (OS: HR¼ 0.47; PFS:
HR¼ 0.56; RR¼ 38% vs. 13% in TC3 or IC3 patients
comparing atezolizumab with docetaxel), while patients with
the lowest PD-L1 levels (TC0 and IC0) did not appear to
benefit from atezolizumab (OS: HR¼ 1.22).58 Median OS was
12.6 months with atezolizumab versus 9.7 months with
docetaxel (HR¼ 0.73, p¼ 0.04). However, there was no dif-
ference between atezolizumab and docetaxel (median OS of
9.7 months in both arms) in patients with little or no expres-
sion of PD-L1. The other study (known as BIRCH) was a
single-arm study in which atezolizumab was used in patients
with PDL1-positive advanced NSCLC.59 PD-L1 expression
was assessed in the same way as in the POPLAR study. Pa-
tients were divided into three cohorts: Cohort 1 had no prior
therapy, Cohort 2 had received one prior chemotherapy, and
Cohort 3 had received at least two prior systemic therapies.
The primary endpoint was RR, which was 26%, 24%, and
27%, respectively, for the three cohorts of patients who had a
high expression of PD-L1. The response rates were 19%, 17%,
and 17%, respectively, for patients who had a medium to high
expression of PDL1. Another phase II study of atezolizumab
(FIR) in stage IIIB/IV NSCLC patients based on PD-L1
expression was also reported recently.60 Cohort 1 included
chemonaive patients, Cohort 2 included patients who had
received no less than two lines of systemic treatment without
brain metastasis, and Cohort 3 included patients who had
received no less than two lines of systemic treatment and were
with treated asymptomatic brain metastasis. Atezolizumab
dose and PD-L1 expression and scoring system were the same
as in POPLAR and BIRCH. Patients with PD-L1 TC 2/3 and/
or IC 2/3 tumors were enrolled. Of the 138 patients enrolled,
the response rates were 29%, 17%, and 17% in Cohort 1,
Cohort 2, and Cohort 3, respectively, while the highest
response rates were seen in patients with PD-L1 TC3 or IC3
tumors (29%, 26%, and 25%, respectively). It seems that
atezolizumab had a remarkable activity in NSCLC patients
with high PD-L1 expression regardless of the line of
treatment.
A phase Ib study that evaluated atezolizumab in combina-
tion with carboplatin plus either paclitaxel (Arm C), peme-
trexed (Arm D) or weekly nab-paclitaxel (Arm E) was done in
chemonaive locally advanced or metastatic NSCLC, and pre-
liminary results are available.61 Patients received atezolizu-
mab every 3 weeks with a standard chemotherapy dosing for
four to six cycles followed by atezolizumab maintenance
therapy until disease progression. Across all arms, the RR was
67% (20 of 30), including 60% in Arm C (three of five), 75%
in Arm D (eight of 12), and 62% in Arm E (eight of 13). Phase
III studies are ongoing.3.4. DurvalumabDurvalumab (MEDI-4736) is a human IgG1 monoclonal
antibody targeting PD-L1. Preliminary results of an ongoing
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12 Y.-M. Chen / Journal of the Chinese Medical Association 80 (2017) 7e14phase I/II, multicenter study of durvalumab evaluating the
safety and clinical activity of durvalumab in patients with
multiple solid tumor types including NSCLC were reported
recently.62 Durvalumab was administered at 10 mg/kg IV
every 2 weeks until unacceptable toxicity, disease progres-
sion, or 12 months was reached. Tumor PD-L1 expression
was assessed using Ventana PD-L1 IHC (SP263). As of
October 31, 2014, 198 patients had been treated. There were
149 patients evaluable for response, and RR was 14% (23%
in tumor PD-L1 positive patients). The response rate was
higher in squamous (21%) than in nonsquamous patients
(10%). Durvalumab has been accelerated into phase III
clinical development in NSCLC at present.3.5. AvelumabAvelumab (MSB0010718C) is a fully human anti-PD-L1
IgG1 monoclonal antibody. By retaining a native Fc-region,
avelumab is also able to induce antibody-dependent cell-
mediated cytotoxicity.
There was a preliminary report of a phase Ib expansion
trial evaluating safety and clinical activity in patients with
advanced NSCLC progressing after platinum-based chemo-
therapy.63 Patients were treated with avelumab at 10 mg/kg
every 2 weeks until disease progression, confirmed complete
response, or intolerable toxicity. A follow-up analysis of 184
patients was performed. Objective responses were observed
in 22 (12%) patients. Median PFS was 2.7 months. The RR in
PD-L1 positive patients (n¼ 118) was 14.4% and 10.0% in
PD-L1 negative patients (n¼ 20).
4. Surrogate marker
Among predictors for checkpoint inhibitor therapy, tumor
PD-L1 immunohistochemical staining is the most frequently
used predictor for anti-PD-1 and anti-PD-L1 immuno-
therapy.64,65 There are at least four kinds of kits or platforms
for detection of tumor PD-L1 expression. Some studies also
count PD-L1 expression in immune cells and correlate both
tumor and immune cell PD-L1 expression with treatment
response. Most studies assess PD-L1 expression in tumor
cells and regard membrane staining as most signifi-
cant.46,47,52,64 In general, there is a trend of higher response
rates in the PD-L1 expression positive patients compared
with the PD-L1 expression negative patients, although in
some studies this difference was not significant (Table 2). Up
to now, PD-L1 expression is not a perfect biomarker, since
most studies also report significant response rates (3e20%)
in PD-L1 expression negative patients.65 Other proposed
methodologies include examination of mutational burden by
genomics.66
In conclusion, with the approval of both nivolumab and
pembrolizumab in the treatment of second-line NSCLC
treatment, the use of immune checkpoint inhibitors for the
treatment of NSCLC is firmly established. The ongoing
plethora of phase III studies of PD-1 and PD-L1 inhibitors,
either alone or in combination with chemotherapy, targeted
13Y.-M. Chen / Journal of the Chinese Medical Association 80 (2017) 7e14therapy, radiotherapy, or immunotherapy in different stages of
NSCLC, will serve to clarify and likely expand their use in
NSCLC treatment. However, there are still many challenges
ahead for oncologists, including determining the optimal time
for integration of immunotherapy into the lifetime course of
NSCLC patient treatment. Despite these challenges, immu-
notherapy with checkpoint inhibitor has already become the
newest, most important, and most novel treatment modality
during the decade following the discovery of targeted therapy.
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